Anticipated benefits and surprising effects of daclizumab in multiple sclerosis

Lancet Neurol. 2010 Apr;9(4):337-8. doi: 10.1016/S1474-4422(10)70032-6. Epub 2010 Feb 15.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • CD56 Antigen / metabolism
  • Cell Proliferation / drug effects
  • Daclizumab
  • Humans
  • Immunoglobulin G / therapeutic use*
  • Immunosuppressive Agents / therapeutic use*
  • Killer Cells, Natural / drug effects
  • Killer Cells, Natural / physiology
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / physiopathology
  • Randomized Controlled Trials as Topic
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / physiology
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • CD56 Antigen
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Daclizumab